病毒載體合作與授權協議（2016-2026）

病毒載體交易的權威基準

病毒載體領域的合作是由其作為病毒載體和細胞療法中關鍵基礎技術的作用所驅動的，其合約結構反映了平台使用權、生產能力和技術專長。

本報告對 450 多項病毒載體合作與許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告對病毒載體領域的合約實際建構方式進行了精確闡述。

• 類似交易的可靠基準
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
• 定義切合實際的市場參數
• 清晰洞察基於載體類型、應用和合作夥伴概況的合約條款差異。
• 支持基於證據的評估和合約結構確定。
• 讓內部討論基於實際交易數據，而不是僅基於假設。
• 了解主要公司的交易方式
• 在平台主導和容量受限的環境下，可視化合作夥伴行為模式和迭代合約結構。
• 完全透明地了解合約的結構和執行情況
• 本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和付款條款
• 關鍵合約條款和保護措施
• 這種透明度對於理解病毒載體領域合作關係中價值、風險和控制權的分配至關重要。在涉及生產規模擴大、供應限制和平台整合等領域，其重要性更為突出。
• 專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

• 建置及基準測試平台及底層技術交易
• 在清晰的市場環境下準備談判
• 許可、生產和合作夥伴評估
• 利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

• 超過 450 項與病毒載體相關的合作和授權協議。
• 財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
• 可全文搜尋的合約目錄（按公司、向量類型和用例）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 合約趨勢、重大交易和活躍合約方分析。
• 病毒載體交易的可靠依證參考資料
• 本報告結合全面的合約資料涵蓋和詳細的合約層面分析，為如何建立、談判和評估病毒載體領域的夥伴關係提供了可靠的、依證的參考。

目錄

執行摘要

第1章：引言

第2章：病毒載體交易趨勢

• 過去幾年病毒載體合作
• 病毒載體交易中最活躍的參與者
• 病毒載體合約：按合約類型分類
• 病毒載體合約：按治療領域分類
• 病毒載體合約：按行業分類
• 病毒載體合約條款
  • 標題金額
  • 預付款
  • 里程碑付款
  • 權利金費率

第3章 主要病毒載體合約

• 以合約價值排名的暢銷病毒載體合約

第4章：病毒載體領域最活躍的締約方

• 病毒載體領域最活躍的締約方
• 最活躍的病毒載體領域中各簽約方的公司簡介

第5章：病毒載體合約目錄

• 病毒載體訂閱目錄

第6章：病毒載體合約：依技術類型分類

• 合約目錄
• 合約目錄：依公司分類的病毒載體合約（A-Z）
• 合約目錄：依合約類型分類的病毒載體合約
• 合約目錄：按治療領域分類的病毒載體合約
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• 關於當前合作夥伴關係
• 關於現行協議
• Current Partnering 最新報告列表

The definitive benchmark for viral vector dealmaking

Viral vector partnering is driven by its role as a critical enabling technology for gene and cell therapies, with deal structures reflecting platform access, manufacturing capabilities, and technical expertise.

This report provides a comprehensive and structured analysis of 450+ viral vector collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how viral vector deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by vector type, application, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a platform-driven and capacity-constrained landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within viral vector partnerships, particularly in areas involving manufacturing scale-up, supply constraints, and platform integration.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark platform and enabling technology transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing, manufacturing, and collaboration partners
• Support internal strategy with robust, defensible data
• What's included
• 450+ viral vector collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, vector type, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for viral vector dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how viral vector partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in viral vector dealmaking

• 2.1. Introduction
• 2.2. Viral vector deals over the years
• 2.3. Most active viral vector dealmakers
• 2.4. Viral vector deals by deal type
• 2.5. Viral vector deals by therapy area
• 2.6. Viral vector deals by industry sector
• 2.7. Deal terms for viral vector deals
  • 2.7.1 Viral vector deals headline values
  • 2.7.2 Viral vector deal upfront payments
  • 2.7.3 Viral vector deal milestone payments
  • 2.7.4 Viral vector royalty rates

Chapter 3 - Leading viral vector deals

• 3.1. Introduction
• 3.2. Top viral vector deals by value

Chapter 4 - Most active viral vector dealmakers

• 4.1. Introduction
• 4.2. Most active viral vector dealmakers
• 4.3. Most active viral vector deals company profiles

Chapter 5 - Viral vector contracts dealmaking directory

• 5.1. Introduction
• 5.2. Viral vector contracts dealmaking directory

Chapter 6 - Viral vector dealmaking by technology type

• Deal directory
• Deal directory - Viral vector deals by company A-Z
• Deal directory - Viral vector deals by deal type
• Deal directory - Viral vector deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Viral vector deals since 2016
• Figure 2: Active viral vector dealmaking activity since 2016
• Figure 3: Viral vector deals by deal type since 2016
• Figure 4: Viral vector deals by therapy area since 2016
• Figure 5: Viral vector deals by industry sector since 2016
• Figure 6: Viral vector deals with a headline value
• Figure 7: Viral vector deals with an upfront value
• Figure 8: Viral vector deals with a milestone value
• Figure 9: Viral vector deals with a royalty rate value
• Figure 10: Top viral vector deals by value since 2016
• Figure 11: Most active viral vector dealmakers since 2016
• Figure 12: Viral vector deals by technology type since 2016